BioTime Inc (BTX) Drops 9.1% on January 11

Equities Staff |

BioTime Inc (BTX) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 9.1% to $2.72, a loss of $-0.2722 per share. Starting at an opening price of $2.97 a share, the stock traded between $2.61 and $3.01 over the course of the trading day. Volume was 420,700 shares over 1,869 trades, against an average daily volume of 307,465 shares and a total float of 94.89 million.

The losses send BioTime Inc down to a market cap of $257.9 million. In the last year, BioTime Inc has traded between $5.95 and $2.20, and its 50-day SMA is currently $3.41 and 200-day SMA is $3.62.

BioTime Inc is a biotechnology company. The Company is engaged in the biomedical research and product development in regenerative medicine including human embryonic stem cell and induced pluripotent stem cell technology.

BioTime Inc is based out of Alameda, CA and has some 120 employees. Its CEO is Michael D. West / Aditya Mohanty / Pedro Lichtinger.

For a complete fundamental analysis analysis of BioTime Inc, check out Equities.com’s Stock Valuation Analysis report for BTX. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…